Factors Associated With Survival in Patients Having Pneumocystis Jirovecii

NCT06173453 | Unknown

• 1 other identifier: 8722
• Study Type: observational
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

Pneumocystis jirovecii is a fungus that can colonize the airways of some patients and be responsible for a disease called pneumocystosis in other patients and mainly in immunocompromised patients. Pneumocystosis was mainly linked to HIV in the 1990s, but with the advent of new immunosuppressive molecules used in cancers or autoimmune diseases and with the increase in the number of transplants, the epidemiology has changed in recent years. Studies on P. jirovecii-related mortality are only based on patients with pneumocystosis. As a result, patients who are simply colonized or patients who are sick but not treated are not taken into account in these studies. The investigators therefore wish to study the overall mortality at six weeks and at three months in all patients with a positive sample for P. jirovecii

Conditions

Pneumocystis Jirovecii Infection

Keywords

P jirovecii Infection; Pneumocystis Infections; Pneumocystis jirovecii Infection; Pneumocystis jirovecii; Pneumonia; Pneumocystis

Outcome Measures

Primary Outcomes (1)

• Survival at six weeks and three months after infection

  six weeks after infection

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients with a positive respiratory sample for P. jirovecii

You may qualify if:

• Adult patients with a positive respiratory sample for P. jirovecii cared for in Strasbourg University Hospitals between 01/01/2016 and 31/12/2018. Positive samples are defined as a direct examination finding cysts or trophozoites after staining with May-Grunewald-Giemsa and/or Gomori-Grocott, a positive P. jirovecii PCR on sputum, tracheal aspirates or bronchial fluid -alveolar
• Subject not objecting to the reuse of their data for scientific research purposes.

You may not qualify if:

• \- Subject having expressed its opposition to the reuse of its data for scientific research purposes.

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

Pneumocystis Infections; Pneumonia; Pneumonia, Pneumocystis

Condition Hierarchy (Ancestors)

Mycoses; Bacterial Infections and Mycoses; Infections; Respiratory Tract Infections; Lung Diseases; Respiratory Tract Diseases; Lung Diseases, Fungal

Central Study Contacts

François DANION, MD

CONTACT

33 3 69 55 15 88; Francois.danion@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 15, 2023
• First Posted: December 15, 2023
• Study Start: January 1, 2023
• Primary Completion: August 10, 2025
• Study Completion: October 10, 2025
• Last Updated: December 15, 2023

Record last verified: 2023-06

Locations

FR (1)